Title Page

The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus: A systematic review and meta-analysis

Sasidharanpillai Sabeena[1*], Nagaraja Ravishankar[2], S Robin[3], Sabitha Sasidharan Pillai[4]

Article type: **Systematic review and meta-analysis**

Short title: RSV activity during the COVID-19 pandemic

1.Dr Sasidharanpillai Sabeena*,

MBBS, DGO, PhD

Allure Residency, Jhamsikhel,

Lalitpur,

Kathmandu, Nepal-44600

Email: sabeenauthradam@gmail.com

Phone-+977-9808187821

ORCID: https://orcid.org/0000-0002-2099-9312

2. Nagaraja Ravishankar [2]

MSc, PhD

Assistant Professor

Department of Biostatistics

Vallabhbhai Patel Chest Institute

University of Delhi

Vijay Nagar Marg, Art Faculty, University Enclave,

New Delhi, Delhi 110007, India

Email: ravi8133@gmail.com

ORCID: https://orcid.org/ **0000-0002-9533-039X**

3. Dr Sudandiradas Robin [3]

MPH

Research Officer

Manipal Institute of Virology

Manipal Academy of Higher Education

Email: robinnaturedoc@gmail.com

ORCID: https://orcid.org/0000-0002-4340-9434

4 Dr Sabitha Sasidharan Pillai[4]

MBBS, DCH, DNB

Paediatric Endocrinology Fellow,

Warren Alpert Medical School of Brown University, Providence,

593 Eddy Street, Providence, RI 02903, USA

Email id: sabitha_sasidharan_pillai@brown.edu

https://orcid.org/0000-0002-0391-3759

Corresponding Author name:

[1]Dr Sasidharanpillai Sabeena

MBBS, DGO, PhD

Allure Residency, Jhamsikhel,

Lalitpur,

Kathmandu, Nepal-44600

Email id:sabeenauthradam@gmail.com

Phone no: +977-9808187821

https://orcid.org/0000-0002-2099-9312

Word count:

Abstract: 211

Manuscript: 2312

Abstract

The COVID-19 pandemic has changed the epidemiology of RSV infection which accounts for most bronchiolitis and viral pneumonias in infants. This systematic review and meta-analysis aimed to quantitatively evaluate the effect of the COVID-19 pandemic on respiratory syncytial virus (RSV) associated bronchiolitis among hospitalised infants. The study protocol was registered in the PROSPERO database (CRD42022314000) and was designed based on PRISMA guidelines updated in May 2020. The meta-analysis component was modified appropriately to synthesise the pooled proportion of infants having RSV-associated bronchiolitis before the COVID-19 pandemic in 2019 and during the pandemic with 95% confidence interval (CI). Eight qualified studies from Europe and China, including 109,186 symptomatic cases of bronchiolitis before the pandemic in 2019 and 61,982 cases in 2020-2021 were pooled by random-effects meta-analysis. The quantitative analysis included laboratory-confirmed RSV infection in 7691 infants with bronchiolitis reported before the pandemic in 2019. Meanwhile, during the pandemic, 4964 bronchiolitis cases were associated with RSV infection. The pooled proportion of RSV-associated bronchiolitis cases before the pandemic in 2019 was 16.74% (95% CI 11.73, 22.43%). The pooled proportion of confirmed RSV cases during the pandemic in 2020/2021 was 19.20 % (95% CI 12.01, 27.59%). There was an increase in RSV activity after the relaxation of stringent public health measures during the COVID-19 pandemic.

Keywords: bronchiolitis, COVID-19, pandemic, respiratory syncytial virus, SARS-CoV-2

The impact of COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus: A systematic review and meta-analysis

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious novel coronavirus that emerged in late 2019, leading to the coronavirus disease 2019 (COVID-19) pandemic. The non-pharmaceutical interventions such as masking, use of hand sanitisers and various public health measures of lockdowns, travel restrictions, social distancing, isolation, and quarantines helped to control the transmission in the initial months. Compared to the pre-pandemic seasons, the epidemiology of other common viral respiratory infections was significantly affected during the pandemic[1]. There was a decrease in respiratory viral infections, including respiratory syncytial virus (RSV), due to various non-pharmaceutical interventions implemented to curb the pandemic. These public health measures reduced the transmission of enveloped viruses such as influenza and (RSV)[2]. Lower respiratory tract infections or bronchiolitis in infants lead to increased hospitalisations and mortality during the winter season. The primary aetiology of bronchiolitis is infection by RSV, which results in recurrent wheeze and asthma in childhood[3]. Most of the bronchiolitis cases occur in low-income countries with limited RSV surveillance, which demands molecular diagnostic facilities. Over the past year, not a single RSV case was reported in many countries during the winter season, which extended between the last months of 2020 and early 2021. Many developed countries in the northern and southern hemispheres reported an unexpected surge in the RSV cases during the summer of 2021[4].

COVID-19 pandemic has led to alterations in the epidemiology of RSV infection which accounts for most bronchiolitis and viral pneumonias in infants. During the spring or summer seasons, a resurgence in areas reporting a meagre number of RSV cases was noted globally during the pandemic. Monitoring the effect of COVID-19 on the circulation of RSV infection in infants is essential as there are no specific vaccines or antivirals for this virus. This

systematic review and meta-analysis aimed to analyze the effect of the COVID-19 pandemic on RSV-associated bronchiolitis among hospitalised infants.

Methods

This systematic review was commenced after excluding registered or ongoing systematic reviews regarding the impact of the COVID-19 pandemic on bronchiolitis (lower respiratory tract infection) due to respiratory syncytial virus in the PROSPERO database. The study protocol was registered in the PROSPERO database (CRD42022314000) and can be accessed at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022314000.

The systematic review and meta-analysis were performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines updated in May 2020[5]. The meta-analysis component was modified appropriately to synthesise the pooled proportion of paediatric bronchiolitis cases tested positive for RSV before the COVID-19 pandemic in 2019 and during the pandemic.

Description of the condition

Bronchiolitis: Bronchiolitis is the most common lower respiratory tract viral infection caused by RSV among children below two years[6], followed by rhinovirus and human Boca virus. The main clinical features of bronchiolitis are cough, chest recession or tachypnoea, crackles on chest auscultation or the first episode of acute wheeze[7].

Extended severe acute respiratory infection (SARI) due to RSV: Symptoms of cough/shortness of breath within the last ten days necessitating hospitalisation due to RSV is defined as extended severe respiratory infection due to RSV[8].

RSV infection: RSV infection was confirmed in symptomatic cases by real-time reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assay or virus isolation.

2 Study Protocol

An electronic search of PubMed/MEDLINE, Scopus and Google Scholar was carried out for all the articles in English published between January 2020 and March 2022 regarding the impact of the COVID-19 pandemic on bronchiolitis or lower respiratory tract infection due to the respiratory syncytial virus using search terms such as "impact" AND "COVID-19" OR "SARS-CoV-2" AND "RSV" NOT "vaccines". The manual library search for articles published in peer-reviewed journals was carried out. The references of retrieved articles were examined to increase the search sensitivity.

3 Inclusion process and criteria

Observational studies in English reporting the number of immunocompetent paediatric cases aged two years or below having bronchiolitis or lower respiratory tract infection due to RSV infection were included. Conference abstracts and commentaries were excluded. The studies reporting the data among older children and adults were eliminated. The articles reporting the RSV activity among immunocompromised cases were also not considered.

4 Data extraction

A validated proforma detailing the name of the first author, year of publication, study area, number of cases with bronchiolitis/lower respiratory tract infection (LRTI) attended the hospitals in 2019 and during the pandemic, number of laboratory-confirmed RSV positive cases in 2019 and during the pandemic was prepared. A three-stage selection of published articles was carried out for the final inclusion. One reviewer evaluated the titles of the records for the relevance for inclusion in the study (n=5479). Studies applicable for the review were

moved to the second stage after eliminating irrelevant topics and duplicates (n=5290). In the second stage, the abstracts of the studies were obtained and were independently examined by two reviewers (n=97). After reviewing the abstracts, full texts of studies were procured, which were inspected by two reviewers independently (n=50). The corresponding authors were communicated electronically if further clarification was needed. Manual library searches for articles in peer-reviewed journals were carried out, and references of retrieved articles were reviewed to increase the search sensitivity. The PRISMA 2020 flow diagram[5] (**Fig 1**) depicts the study selection process. The last date of the search was on March 22, 2022.

5 Risk of bias (quality) assessment in individual studies

To assess the risk of bias in individual studies (quality assessment), chosen after the abstract and content review, the National Institutes of Health checklist for observational, cohort and cross-sectional studies was used[9]. The studies with a minimum score of eight or above, seven, or five or less than five "Yes responses" were considered good, fair, and poor quality, respectively. For cross-sectional studies, question numbers 1, 2, 3, 4, 5 and 11 were applicable. The responses to the remaining eight questions (6-10, 12, 13, 14) were not applicable (NA). The studies with six "Yes" responses were considered good, and those with four /five were taken as fair. The studies with less than four "Yes responses" were considered poor quality. The quality of the studies was evaluated by two reviewers independently.

6 Statistical analysis

The meta-analysis was accomplished in STATA version 13.0 (College Station, Texas 77, 845 USA). The forest plots were constructed using metaprop package in STATA. The pooled proportion of symptomatic cases of RSV-associated bronchiolitis or lower respiratory tract infections before the pandemic in 2019 and during the pandemic was reported with 95% CI. Chi-square statistic (Q statistic) and I^2 index to quantify the heterogeneity was noted as

considerable heterogeneity across the studies was expected. The I^2 value ranging between 0% to 24% specifies consistency. I^2 values of 25%-49% imply low heterogeneity and 50-74% points toward moderate heterogeneity. The I^2 value varying between 75%-100% is indicative of high heterogeneity[10].

7 Assessment of Publication bias

Egger's test was used to report the publication bias. Weighted linear regression with standardised effect estimate and precision was considered the dependent and independent variables, respectively. In the present study, the $\log_e$ proportion of RSV positive bronchiolitis cases and precision were considered the effect estimate and 1/standard error of $\log_e$ proportion rate, respectively. Weights were allotted using the inverse variance approach (1/variance of the effect estimate). A statistically significant bias coefficient is the evidence for publication bias.

Results

Included studies

We identified and screened 189 articles and systematically reviewed fifty full texts. The eight qualified studies for the meta-analysis were from Spain, Italy, France and China, including 109,186 cases of bronchiolitis before the pandemic in 2019 and 61,982 cases during the pandemic[11–18]. All these studies were qualified, as good as shown in **Table 1**. These studies reported 7691 laboratory-confirmed RSV associated lower respiratory tract infections in 2019 and 4964 during the pandemic in 2020/21. Two studies from Spain and France were multicenteric [16, 18]. The highest number of symptomatic cases were admitted in the multicentric study from Spain[16] before and during the pandemic. All the studies chosen for the meta-analysis reported a decrease in bronchiolitis cases with increased RSV positivity during the pandemic. The highest rate of RSV positivity in bronchiolitis noted before the

pandemic was 70.2%. Meanwhile, during the COVID-19 pandemic RSV was the causative agent in up to 77.8% of bronchiolitis cases, as in **Table 1**. Both the studies from China and one multicenteric study from Spain included cases seen during the entire year 2019 and whole 2020. Guitart et al, Casalegno et al, Stera et al and Fourgeaud et al included infants with bronchiolitis admitted during the RSV season spanning over eight to ten months.

Meta-analysis

The pooled proportion of RSV-associated bronchiolitis cases before the pandemic in 2019 was 16.74% (95% CI 11.73%,22.43%) as in **Fig 2**. **Fig 3** represents the pooled proportion of RSV cases among infants during the pandemic in 2020/2021, as 19.20% (95% CI 12.01%,27.59%). As the I^{2-}value was>90%, a high heterogeneity was observed between the studies.

Publication bias

As shown in **Table 2,** the *p*-value for the bias coefficient was not statistically significant. Hence there was no publication bias.

Discussion

The studies qualified for this meta-analysis were from China and Europe. The pooled proportion of RSV positivity in bronchiolitis cases was more during the COVID-19 pandemic. The decline in hospitalised bronchiolitis cases or lower respiratory tract infections during the COVID-19 pandemic might be attributed to reduced admission rates for non-SARS-CoV-2 respiratory infections. Many countries such as Italy, Germany, Belgium, Vienna and Brazil reported no hospitalised bronchiolitis cases during the winter season[12,

19–21]. Similarly, the study from Israel reported a temporal shift of RSV epidemic to spring season from winter[22]. During the COVID-19 pandemic, hospitals in Spain reported a steep decline in bronchiolitis cases and RSV positivity with seven months delayed RSV peak in July 2021[16]. Meanwhile, France reported a rise in RSV cases during the late winter months of 2021 after the second national lockdown in December 2020 [15]. Japan observed no reporting of RSV cases in 2020, followed by a resurgence in July 2021[23]. The tropical country of Thailand, located in South East Asia, witnessed a delayed RSV season in 2020 among children with influenza-like illness[24]. There was an increase in the number of confirmed RSV cases across all age groups during the spring season of the year 2020 in Australia and South Africa[25, 26]. The inter-seasonal rise in RSV infections during the summer was observed in the northern and southern hemispheres[27, 28]. Italy reported a significant decline in hospitalised cases of bronchiolitis in 2020, with no bronchiolitis cases in 2021. However, a late RSV peak was not observed in Italy, unlike many countries[12]. In 2020, China reported a decrease in lower respiratory tract infection among children, mainly due to the strict public health measures to contain the SARS-CoV-2 infection. The studies from Shanghai and Xiamen reported a decline in RSV activity among the hospitalised children. Both the studies observed a mild increase in RSV and influenza activity during the winter months without a temporal shift in seasonality[14, 29]. However, another single centre study from Hangzhou reported a marked rise in RSV cases during the winter season of 2020, comparable to the pre-pandemic period[17].

Respiratory viral infections at young age facilitate the building up of trained immunity. Apart from a relatively young population of Africa compared to other parts of the world, prior exposure to other cross-reactive viruses is another causative factor for low SARS-CoV-2 related morbidity and mortality in Sub-Saharan Africa[30]. However, countries perceiving a very low number of RSV cases are at an increased risk of resurgence of RSV infection,

mainly among older RSV-naïve children[31]. Sentinel surveillance of RSV is better in many European countries than in other parts of the world[32, 33]. There is no data regarding the RSV activity from the majority of the Asian and African countries having higher RSV associated disease burden [34].

Causes of heterogeneity

The main heterogeneity was in the number of bronchiolitis cases enrolled before and during the pandemic. Two multicentric studies enrolled a higher number of hospitalised cases compared to single centre studies. Even though six studies confirmed RSV infection by real time reverse transcription polymerase chain reaction (RT-PCR), studies from China detected the RSV infection by direct immunofluorescence assay [14, 17].

Even though immunofluorescence assay is a cost-effective, reliable, point-of-care assay for the diagnosis of RSV infection, sensitivity is less compared to PCR [35]. Another disparity was in the time of the year during which the samples were procured from paediatric bronchiolitis cases. Although six studies enrolled infants below one year, two studies incorporated cases below two years.

Limitation

Major limitation was the heterogeneity of studies pooled for quantitative synthesis. Before the COVID-19 pandemic, there was no routine testing of bronchiolitis samples for RSV from developing countries in South East Asia, Africa and Latin America. All the studies included in the meta-analysis were from Europe and China. Even though there were studies from other parts of the world reporting low RSV activity among infants during the COVID-19 pandemic, very few studies reported RSV positivity. The studies pertaining to RSV surveillance from the US, Germany and South Africa could not be included for meta-analysis due to lack of

data among infants [26, 36–39]. During the pandemic the reduction in testing for non-SARS-CoV-2- respiratory viruses might have resulted in lack of data from developing countries [40].

During the coming seasons, health care professionals and hospitals must be prepared to manage the increasing number of symptomatic RSV cases. Our systematic review will be beneficial for European Union funded PROMISE project initiated in November 2021 which aims RSV surveillance and immunisation in Europe[41]. This review emphasises the importance of promoting RSV maternal vaccines and passive childhood immunisation with monoclonal antibodies (mAbs).

Conclusion

There was an increase in RSV activity after relaxing stringent public health measures during the COVID-19 pandemic in the northern and southern hemispheres. Efforts for the diagnosis and surveillance for RSV must be reinforced along with influenza and SARS-CoV-2 viruses to minimise the burden of hospitalisation and mortality among infants.

References

1. Britton PN, Hu N, Saravanos G, et al (2020) COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health 4:e42–e43. https://doi.org/10.1016/S2352-4642(20)30307-2

2. Takashita E, Kawakami C, Momoki T, et al (2021) Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 15:488–494. https://doi.org/10.1111/irv.12854

3. Blanken MO, Rovers MM, Molenaar JM, et al (2013) Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. New England Journal of Medicine 368:1791–1799. https://doi.org/10.1056/NEJMoa1211917

4. Williams TC, Sinha I, Barr IG, Zambon M (2021) Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic. Eurosurveillance 26:2100186. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100186

5. Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

6. Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, et al (2020) Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis in the pre-COVID-19 pandemic era. PLOS ONE 15:e0242302. https://doi.org/10.1371/journal.pone.0242302

7. NICE (2021) Bronchiolitis in children: diagnosis and management. National Institute for Health and Care Excellence (NICE), London

8. WHO Case definitions. https://www.who.int/teams/control-of-neglected-tropical-diseases/yaws/diagnosis-and-treatment/global-influenza-programme. Accessed 7 Dec 2021

9. Study Quality Assessment Tools | NHLBI, NIH. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 27 Sep 2020

10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557

11. Guitart C, Bobillo-Perez S, Alejandre C, et al (2022) Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic. BMC Infectious Diseases 22:84. https://doi.org/10.1186/s12879-022-07041-x

12. Stera G, Pierantoni L, Masetti R, et al (2021) Impact of SARS-CoV-2 Pandemic on Bronchiolitis Hospitalizations: The Experience of an Italian Tertiary Center. Children (Basel) 8:556. https://doi.org/10.3390/children8070556

13. Curatola A, Lazzareschi I, Bersani G, et al (2021) Impact of COVID-19 outbreak in acute bronchiolitis: Lesson from a tertiary Italian Emergency Department. Pediatr Pulmonol 56:2484–2488. https://doi.org/10.1002/ppul.25442

14. Liu P, Xu M, Cao L, et al (2021) Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. Virol J 18:159. https://doi.org/10.1186/s12985-021-01627-8

15. Fourgeaud J, Toubiana J, Chappuy H, et al (2021) Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis 40:2389–2395. https://doi.org/10.1007/s10096-021-04323-1

16. Torres-Fernandez D, Casellas A, Mellado MJ, et al (2021) Acute bronchiolitis and respiratory syncytial virus seasonal transmission during the COVID-19 pandemic in Spain: A national perspective from the pediatric Spanish Society (AEP). J Clin Virol 145:105027. https://doi.org/10.1016/j.jcv.2021.105027

17. Ye Q, Liu H (2022) Impact of non-pharmaceutical interventions during the COVID-19 pandemic on common childhood respiratory viruses - An epidemiological study based on hospital data. Microbes Infect 24:104911. https://doi.org/10.1016/j.micinf.2021.104911

18. Casalegno J-S, Ploin D, Cantais A, et al (2021) Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhône Loire, France. Eurosurveillance 26:2100630. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100630

19. Diesner-Treiber SC, Voitl P, Voitl JJM, et al (2021) Respiratory Infections in Children During a Covid-19 Pandemic Winter. Front Pediatr 9:740785. https://doi.org/10.3389/fped.2021.740785

20. Van Brusselen D, De Troeyer K, Ter Haar E, et al (2021) Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr 180:1969–1973. https://doi.org/10.1007/s00431-021-03968-6

21. Varela FH, Scotta MC, Polese-Bonatto M, et al (2021) Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community. J Glob Health 11:05007. https://doi.org/10.7189/jogh.11.05007

22. Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, et al (2021) Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill 26:. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100706

23. Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N (2021) Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan. Emerg Infect Dis 27:2969–2970. https://doi.org/10.3201/eid2711.211565

24. Thongpan I, Vichaiwattana P, Vongpunsawad S, Poovorawan Y (2021) Upsurge of human rhinovirus infection followed by a delayed seasonal respiratory syncytial virus infection in Thai children during the coronavirus pandemic. Influenza and Other Respiratory Viruses 15:711–720. https://doi.org/10.1111/irv.12893

25. Zheng Z, Pitzer VE, Shapiro ED, et al (2021) Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. JAMA Netw Open 4:e2141779. https://doi.org/10.1001/jamanetworkopen.2021.41779

26. Tempia S, Walaza S, Bhiman JN, et al (2021) Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill 26:. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2001600

27. Saravanos GL, Hu N, Homaira N, et al (2022) RSV Epidemiology in Australia Before and During COVID-19. Pediatrics 149:e2021053537. https://doi.org/10.1542/peds.2021-053537

28. Respiratory Syncytial Virus (RSV) in Florida | Florida Department of Health. https://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus/. Accessed 2 Mar 2022

29. Wang J, Xiao T, Xiao F, et al (2021) Time Distributions of Common Respiratory Pathogens Under the Spread of SARS-CoV-2 Among Children in Xiamen, China. Front Pediatr 9:584874. https://doi.org/10.3389/fped.2021.584874

30. Njenga MK, Dawa J, Nanyingi M, et al (2020) Why is There Low Morbidity and Mortality of COVID-19 in Africa? The American Journal of Tropical Medicine and Hygiene 103:564–569. https://doi.org/10.4269/ajtmh.20-0474

31. Foley DA, Phuong LK, Peplinski J, et al (2022) Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. Arch Dis Child 107:e7. https://doi.org/10.1136/archdischild-2021-322507

32. Mollers M, Barnadas C, Broberg EK, et al (2019) Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017. Euro Surveill 24:1900157. https://doi.org/10.2807/1560-7917.ES.2019.24.40.1900157

33. Teirlinck AC, Broberg EK, Berg AS, et al (2021) Recommendations for respiratory syncytial virus surveillance at national level. European Respiratory Journal. https://doi.org/10.1183/13993003.03766-2020

34. Broor S, Campbell H, Hirve S, et al (2020) Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges. Influenza Other Respir Viruses 14:622–629. https://doi.org/10.1111/irv.12672

35. Shafik CF, Mohareb EW, Youssef FG (2011) Comparison of Direct Fluorescence Assay and Real-Time RT-PCR as Diagnostics for Respiratory Syncytial Virus in Young Children. Journal of Tropical Medicine 2011:e781919. https://doi.org/10.1155/2011/781919

36. Olsen SJ (2021) Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021. MMWR Morb Mortal Wkly Rep 70:. https://doi.org/10.15585/mmwr.mm7029a1

37. Groves HE, Piché-Renaud P-P, Peci A, et al (2021) The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. The Lancet Regional Health – Americas 1:. https://doi.org/10.1016/j.lana.2021.100015

38. Park KY, Seo S, Han J, Park JY (2021) Respiratory virus surveillance in Canada during the COVID-19 pandemic: An epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity. PLoS One 16:e0253451. https://doi.org/10.1371/journal.pone.0253451

39. Oh D-Y, Buda S, Biere B, et al (2021) Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data. Lancet Reg Health Eur 6:100112. https://doi.org/10.1016/j.lanepe.2021.100112

40. Cantú-Flores K, Rivera-Alfaro G, Muñoz-Escalante JC, Noyola DE (2022) Global distribution of respiratory syncytial virus A and B infections: a systematic review. Pathogens and Global Health 0:1–12. https://doi.org/10.1080/20477724.2022.2038053

41. PROMISE 3rd GAM. In: Promise Preparing for RSV immunisation and surveillance in Europe. https://imi-promise.eu/events/promise-3rd-gam/. Accessed 9 Jun 2022

Statements and Declarations

a. Funding: This study was not funded

b. Conflicts of interests/competing interests:

The authors have no relevant financial or non-financial interests to disclose.

c. Availability of Data:

The preprint was published in medRxiv (https : // www. medrxiv. org/ content /10.1101 /2022.04.26.22274244v1) on 27th April. The data that support the findings of this study are available from the corresponding author upon reasonable request (Dr Sasidharanpillai Sabeena, sabeenauthradam@gmail.com).

d. ETHICS STATEMENT

The authors state that this manuscript does not involve any misconduct such as plagiarism, forgery, tampering, improper signature, multiple submission, repeated publication, split publication, etc. The systematic review and meta analysis used published data in indexed journals. Ethical approval to conduct the analysis was not sought as this was a secondary data analysis that requires no approval. No data with a personal identifier was used.

e. Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Sasidharanpillai Sabeena, N Ravishankar, Sudandiradas Robin and Sabitha Sasidharanpillai. The first draft of the manuscript was written by Sasidharanpillai Sabeena and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Figure Captions

Fig 1. PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers and other sources. The flow diagram illustrates the number of studies identified, screened, abstracts/full-text articles included/excluded for the systematic review and meta-analysis.

Fig 2. The Forest Plot of the summary effect size (Proportion of bronchiolitis cases tested positive for RSV before the COVID-19 pandemic) using random-effects model. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence

intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.62%, *p*-value=0.00.

Fig 3. The Forest Plot of the summary effect size (Proportion of RSV positive bronchiolitis cases during the COVID-19 pandemic) using random-effects model. Squares indicate the effect size of individual studies and the extended lines denote 95% confidence intervals (CI). Sizes of squares imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. Test of heterogeneity: $I^{2=}$ 99.69 %, *p*=0.00.